Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility
This is a paid press release. Contact the press release distributor directly with any inquiries.
FDA Approval Granted for Commercial Manufacturing at Rezon Bio’s Warsaw-Duchnice Facility
Business Wire
Wed, February 18, 2026 at 10:01 PM GMT+9 2 min read
WARSAW, Poland, February 18, 2026–(BUSINESS WIRE)–Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide.
The FDA approval of the Warsaw-Duchnice facility follows a comprehensive review process and reflects the maturity of the site’s quality systems, technical capabilities, and operational readiness for commercial supply to the US market. This approval is coming subsequent to previous EMA GMP certification and approval for commercial supply to European markets. Such approval further strengthens Rezon Bio’s ability to support clients in needs to supply EU and US territories and enhances its position as a reliable partner within the Contract Development and Manufacturing Organization (CDMO) landscape.
“This milestone reflects the dedication of our teams to quality, collaboration, and scientific excellence,” said Adriana Kiędzierska-Mencfeld, CEO of Rezon Bio. “The FDA approval of our Warsaw-Duchnice site demonstrates our commitment to meeting applicable international quality and regulatory requirements and the ability to deliver reliable, world-class CDMO services. This achievement opens new possibilities for Rezon Bio and our partners, validating our position within the global CDMO sector as we continue to support clients in bringing critical biologic therapies to market”.
“From a quality perspective, this approval confirms the robustness of the systems, processes, and culture established at our Warsaw-Duchnice site,” said Abdelkader Talha, Vice President Quality at Rezon Bio. “Our focus remains on consistent execution, continuous improvement, and maintaining active engagement with regulatory authorities as we support our partners’ biologics programs”.
Sjouke Hoffman, Site Head at Warsaw-Duchnice, added: “This approval reflects the disciplined work of our teams in establishing robust processes and operational readiness at the Warsaw-Duchnice site. Our infrastructure and multidisciplinary expertise enable us to support both clinical and commercial biologics programs with consistent execution and in alignment with applicable quality and regulatory standards. We are proud to deliver innovative, scientifically robust and reliable solutions for our clients and support the development and availability of high-quality therapies for patients worldwide”.
Rezon Bio’s Warsaw-Duchnice site is a state-of-the-art biologics manufacturing and development center, offering integrated services from early development through commercial production. The multidisciplinary team includes experts in process and analytical development, GMP manufacturing, quality control, and regulatory affairs, ensuring project continuity and reliable delivery of high-quality biologic therapies.
Rezon Bio remains committed to supporting clients worldwide in bringing innovative biologic therapies to market safely, compliantly, and cost-efficiently.
About Rezon Bio
Rezon Bio is a science-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian biologics. Headquartered in Poland, Rezon Bio offers integrated solutions spanning cell line development, commercial drug substance manufacturing, and drug product development, with state-of-the-art facilities, world-class teams, and a proven track record of regulatory and commercial success. Grounded in Polpharma Biologic’s legacy of excellence in biosimilars development and manufacturing, Rezon Bio is committed to delivering value without compromise through innovation, collaboration, analytical excellence, and dedication to patients worldwide.
For more information about Rezon Bio’s facilities, please visit:
View source version on businesswire.com:
Contacts
**Media Contact: **
**Loukiani Chatzinasiou **
loukiani.chatzinasiou@rezonbio.com
Terms and Privacy Policy
Privacy Dashboard
More Info